YEWB — Yew Bio-Pharm Income Statement
0.000.00%
Basic MaterialsHighly SpeculativeMicro Cap
- $0.01m
- $8.98m
- $27.31m
Annual income statement for Yew Bio-Pharm, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2016 December 31st | 2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 51.3 | 40.5 | 37.6 | 27.9 | 27.3 |
Cost of Revenue | |||||
Gross Profit | 3.23 | 5.06 | 10.7 | 0.774 | 3.53 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 49.2 | 37.2 | 36.9 | 26.9 | 24.7 |
Operating Profit | 2.12 | 3.32 | 0.719 | 1.01 | 2.57 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 2.02 | 3.21 | 0.171 | 0.997 | 1.49 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2.01 | 3.21 | -1.21 | 0.986 | 1.46 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 2.01 | 3.21 | -1.32 | 0.986 | 1.46 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 2.01 | 3.21 | -1.32 | 0.986 | 1.46 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.039 | 0.06 | -0.023 | 0.019 | 0.028 |